4 recruiting, 1 active not recruiting. 5 Phase 3, 1 Phase 2.
By phase and status
Follow CLL: new trials by email Literature Review of CLL trials Research Report on CLL
Trials (filtered) newest first · largest first
All 5 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL Rocbrutinib, Pirtobrutinib - CLL / SLL, CLL (Chronic Lymphocytic Leukemia) Phase 3 Recruiting 306 2026-04-23 2026-11-12 A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors Tacabrutideg, Bendamustine, Idelalisib - CLL, Chronic Lymphocytic Leukemia Phase 3 Recruiting 250 2025-04-10 2026-11-12 Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) Sonrotoclax, Zanubrutinib, Venetoclax - CLL Phase 3 Active not recruiting 652 2023-11-11 2026-10-14 A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). Nemtabrutinib, Venetoclax, Rituximab - Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic Phase 3 Recruiting 735 2023-08-08 2026-11-06 Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment Acalabrutinib, Venetoclax - CLL Phase 2 / Phase 3 Recruiting 212 2019-10-11 2023-12-04
Narrower conditions Leukemia, Lymphocytic, Chronic, B-Cell (4) · Chromosome 17 deletion (1) · Leukemia, B-Cell (1) · Recurrence (1)
Broader conditions Chronic Disease (4) · Disease Attributes (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Leukemia (4) · Leukemia, Lymphoid (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Leukemia, B-Cell (3)
Interventions venetoclax (4) · Rituximab (2) · ARQ531 (1) · Bendamustine Hydrochloride (1) · acalabrutinib (1) · idelalisib (1) · obinutuzumab (1) · pirtobrutinib (1) · zanubrutinib (1)
Sponsors BeOne Medicines (2) · Copenhagen University Hospital, Rigshospitalet (1) · Merck Sharp & Dohme LLC (1) · Newave Pharmaceutical Inc (1)
Countries United States (4) · Australia (3) · Brazil (3) · Canada (3) · France (3) · Germany (3) · Italy (3) · Japan (3) · Netherlands (3) · Turkey (Türkiye) (3) · United Kingdom (3) · Argentina (2) · Czechia (2) · Israel (2) · New Zealand (2)
Top investigators Carsten U Niemann, MD, PhD (1)
Results publications PMID 37497921 , PMID 38393694 , PMID 40073834